MP06-04 EXPLORING A NOVEL SYNERGISTIC INTRAVESICAL ONCOLYTIC VIROTHERAPY FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER

Abstract

You have accessJournal of UrologyCME1 May 2022MP06-04 EXPLORING A NOVEL SYNERGISTIC INTRAVESICAL ONCOLYTIC VIROTHERAPY FOR TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER Woodson Smelser, Jian Wang, Sam Chang, and Austin Kirschner Woodson SmelserWoodson Smelser More articles by this author , Jian WangJian Wang More articles by this author , Sam ChangSam Chang More articles by this author , and Austin KirschnerAustin Kirschner More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002523.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: For BCG refractory NMIBC, systemic anti-PD-1 immune checkpoint inhibition is FDA approved as second line therapy. Prior published work by our group demonstrated comparable efficacy and overall survival with intravesical anti-PD-1 treatments in NMIBC in mice. Additionally, oncolytic viral therapy with reovirus has shown pre-clinical efficacy in the bladder & other cancers. We hypothesized that intravesical instilment with both anti-PD-1 inhibitor & oncolytic reovirus would demonstrate a greater synergistic effect than either treatment as monotherapy. METHODS: We investigated an orthotopic mouse model of urothelial bladder cancer using MBT2 cells implanted into the bladders of (n=40) syngeneic, wild-type C3H mice. Groups of 10 mice were treated 14 days after engraftment at the point of palpable tumor for comparison between no treatment, intravesical anti-PD-1, intravesical oncolytic reovirus, & intravesical oncolytic reovirus + anti-PD1. The primary outcome was overall survival; secondary outcomes include long-term immunity & immune milieu changes indicated by mass cytometric evaluation. RESULTS: 40 total mice were engrafted with tumor & then treated. At time of submission, all 10 mice receiving no treatment had died, with median survival of 41 days. Median overall survival for the mice receiving reovirus, anti-PD-1 or anti-PD-1 + reovirus had not been reached. Mice receiving reovirus experienced longer survival than control (HR 14.4; 95% CI 3.9-32.6, p<0.0001), as did mice receiving anti-PD-1 alone (HR 28.4; 95% CI 7.0-115.9, p<0.0001). When compared to control alone, combination therapy with anti-PD-1 & reovirus also demonstrated superior survival (HR 28.4; 95% CI 7.0-115.9, p<0.0001). Comparison between anti-PD-1 and reovirus demonstrated no significant differences in survival (p=0.15). See Figure 1 for Kaplan-Meier analysis comparing survival. CONCLUSIONS: Treatment of mice engrafted with MBT2 orthotopic bladder tumors with intravesical therapy with reovirus, anti-PD-1 antibody, or combination anti-PD-1 antibody & reovirus confer superior survival to intravesical controls. Immune profile analysis examining tumor microenvironment differences in immune response are ongoing with mass cytometry and will further bolster our mechanistic understanding of each therapy. Source of Funding: T32 Grant (WS) © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e78 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Woodson Smelser More articles by this author Jian Wang More articles by this author Sam Chang More articles by this author Austin Kirschner More articles by this author Expand All Advertisement PDF DownloadLoading ...